Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.42 |
| ▸ | JAK2 | O60674 | 6/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338048 | 0.81 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL13659491 | 0.78 | CHEK1 (0.47) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL29848882 | 0.77 | PARP1 (0.33) | PARP1HPGDPDE3BPDE3A | |
| SCHEMBL21050776 | 0.75 | CHEK1 (0.45) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL20314844 | 0.74 | TNF (0.37) | — | |
| SCHEMBL24854119 | 0.72 | CHEK1 (0.42) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL168637 | 0.71 | JAK2 (0.61) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL21099997 | 0.70 | JAK2 (0.56) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL23588625 | 0.70 | PARP1 (0.57) | CHEK1RPS6KA3PARP1 | |
| SCHEMBL15830721 | 0.70 | TSHR (0.46) | CHEK1JAK2RPS6KA3MELKSTK24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4130000-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | CHEK1 415/4885JAK2 451/4885RPS6KA3 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.